The U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to a COVID-19 antibody test created by Beckman Coulter. The antibody test measures the level of antibodies in a patient in response to COVID-19 to provide both a qualitative as well as numerical result of antibodies in arbitrary units (AU). Shamiram R. Feinglass, MD, M.P.H, and Chief Medical Officer (CMO) at Beckman Coulter stated, “Effective and high-quality diagnostic solutions are essential in the fight against COVID-19. Antibody assays like our Access SARS-CoV-2 IgG II test can help researchers quantitatively determine the levels of IgG antibodies and enable them to assess the relative changes of an individual’s immune response to the SARS-CoV-2 virus over time. This information is essential because it helps continually inform therapeutics and vaccine development.”

Read more here.

More on: